Comparison between Goldline Pharmaceutical IPO and Jivial Industries IPO.
Goldline Pharmaceutical IPO is a SME Fixed Price IPO proposed to list at BSE SME while Jivial Industries IPO is a SME Fixed Price proposed to list at BSE SME.
The total issue size of Goldline Pharmaceutical IPO is up to ₹0.00 Cr whereas the issue size of the Jivial Industries IPO is up to ₹0.00 Cr. The final issue price of Goldline Pharmaceutical IPO is and of Jivial Industries IPO is .
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 30,00,000 shares | 13,60,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 2,72,700 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 30,00,000 shares | 16,32,700 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Goldline Pharmaceutical IPO opens on , while Jivial Industries IPO opens on . The closing date of Goldline Pharmaceutical IPO and Jivial Industries IPO is , and , respectively.
Goldline Pharmaceutical IPO P/E ratio is , as compared to Jivial Industries IPO P/E ratio of .
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Goldline Pharmaceutical Ltd.'s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Jivial Industries Ltd.'s revenue increased by 9% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.70 | 94.53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 35.84 | 41.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 38.46 | 47.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | 0.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.38 | 41.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Goldline Pharmaceutical IPO Retail Individual Investors (RII) are offered 0 shares while in Jivial Industries IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Goldline Pharmaceutical IPO and 0 shares in Jivial Industries IPO.
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Goldline Pharmaceutical IPO subscribed in total, whereas Jivial Industries IPO subscribed .
